Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies.
Bewersdorf, J.P., Mi, X., Lu, B., Kuykendall, A., Sallman, D., Patel, M., Stevens, D., Philipovskiy, A., Sutamtewagul, G., Masarova, L., Keiffer, G., Verma, A., Bhagwat, N., Wang, M., Moore, A., Rager, J., Heiser, D., Ro, S., Hong, W.J., Abdel-Wahab, O., Stein, E.M.(2025) Leukemia 39: 765-769
- PubMed: 39856223 
- DOI: https://doi.org/10.1038/s41375-025-02515-8
- Primary Citation of Related Structures:  
9DOD - Department of Medicine; Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Organizational Affiliation: